These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 2512355)

  • 21. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
    Brooks CG; Holscher M; Urdal D
    J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
    Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
    Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
    Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
    J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA; Oldham RK; Yannelli JR
    Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of interferon-alpha and gamma on development of LAK activity from mononuclear cells in breast cancer patients.
    Kamamura Y; Takahashi K; Komaki K; Monden Y
    J Med Invest; 1998 Aug; 45(1-4):71-5. PubMed ID: 9864966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.
    Reiter Z
    Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
    Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
    Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4.
    Salvucci O; Mami-Chouaib F; Moreau JL; Thèze J; Chehimi J; Chouaib S
    Eur J Immunol; 1996 Nov; 26(11):2736-41. PubMed ID: 8921963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
    Ellis TM; Fisher RI
    J Immunol; 1989 Apr; 142(8):2949-54. PubMed ID: 2467946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction.
    Fujiwara T; Grimm EA
    J Immunol; 1992 May; 148(9):2941-6. PubMed ID: 1374105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS; Hargrove ME; Ting CC
    J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity.
    Wu R; Coleman N; Stanley M
    Chin Med J (Engl); 1996 Nov; 109(11):854-8. PubMed ID: 9275369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease of lymphokine (interleukin-2)-activated killer activity in peripheral blood after administration of natural interferon-gamma.
    Yanagawa H; Sone S; Okubo A; Fukuta K; Nishioka Y; Ogura T
    Jpn J Clin Oncol; 1990 Dec; 20(4):356-63. PubMed ID: 2126575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
    Wang Z; Cheng Y; Zheng R; Qin D; Liu G
    Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
    Ortaldo JR; Frey J; Takeshita T; Sugamura K
    Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4.
    Stötter H; Custer MC; Bolton ES; Guedez L; Lotze MT
    J Immunol; 1991 Jan; 146(1):150-5. PubMed ID: 1670602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.